Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

被引：1
|
作者：
Raab, Marc S. [1 ]
Ocio, Enrique M. [2 ]
Thomas, Sheeba K. [3 ]
Guenther, Andreas [4 ,5 ]
Goh, Yeow-Tee [6 ]
Lebovic, Daniel [7 ]
Jakubowiak, Andrzej [8 ]
Song, Dongweon [9 ]
Xiang, F. [10 ]
Patel, Apurva [10 ]
Vanasse, K. Gary [10 ]
Kumar, Shaji [11 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Hosp Schleswig Holstein, Kiel, Germany
[5] Univ Kiel, Kiel, Germany
[6] Singapore Gen Hosp, Singapore, Singapore
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Univ Chicago Med, Chicago, IL USA
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Inst BioMed Res, Cambridge, MA USA
[11] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The Pan-PIM Kinase Inhibitor LGH447 Shows Activity In PIM2-Dependent Multiple Myeloma and In AML Models
    Garcia, Pablo D.
    Langowski, John L.
    Holash, Jocelyn
    Burger, Matthew
    Zang, Richard
    Zavorotinskaya, Tatiana
    Fanton, Christie
    Saci, Abdel
    Growney, Joseph
    Vanasse, K. Gary
    [J]. BLOOD, 2013, 122 (21)
  • [2] The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma
    Marc S. Raab
    Sheeba K. Thomas
    Enrique M. Ocio
    Andreas Guenther
    Yeow-Tee Goh
    Moshe Talpaz
    Nicolas Hohmann
    Sylvia Zhao
    Fang Xiang
    Carl Simon
    K. Gary Vanasse
    Shaji K. Kumar
    [J]. Leukemia, 2019, 33 : 2924 - 2933
  • [3] The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma
    Raab, Marc S.
    Thomas, Sheeba K.
    Ocio, Enrique M.
    Guenther, Andreas
    Goh, Yeow-Tee
    Talpaz, Moshe
    Hohmann, Nicolas
    Zhao, Sylvia
    Xiang, Fang
    Simon, Carl
    Vanasse, K. Gary
    Kumar, Shaji K.
    [J]. LEUKEMIA, 2019, 33 (12) : 2924 - 2933
  • [4] THE COMBINATION OF JAK INHIBITOR RUXOLITINIB, PAN-PIM INHIBITOR LGH447, AND CDK4/6 INHIBITOR LEE011 IN A PRECLINICAL MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASIA
    Pinzon-Ortiz, M.
    Rong, X.
    Saci, A.
    Vanasse, G.
    Schlegel, R.
    Caponigro, G.
    Cao, Z. A.
    [J]. HAEMATOLOGICA, 2014, 99 : 252 - 252
  • [5] The combination of JAK inhibitor, ruxolitinib, pan-PIM inhibitor, LGH447, and CDK4/6 inhibitor, LEE011, in a preclinical mouse model of myeloproliferative neoplasia
    Pinzon-Ortiz, Maria
    Rong, Xianhui
    Saci, Abdel
    Schlegel, Robert
    Vanasse, Gary
    Caponigro, Giordano
    Cao, Z. Alexander
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
    Paino, Teresa
    Gonzalez-Mendez, Lorena
    San-Segundo, Laura
    Corchete, Luis A.
    Hernandez-Garcia, Susana
    Diaz-Tejedor, Andrea
    Algarin, Esperanza M.
    Mogollon, Pedro
    Martin-Sanchez, Montserrat
    Gutierrez, Norma C.
    Mateos, Maria-Victoria
    Garayoa, Mercedes
    Ocio, Enrique M.
    [J]. CANCERS, 2020, 12 (10) : 1 - 20
  • [7] THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO AND IN VIVO MODELS OF MULTIPLE MYELOMA
    Paino, T.
    San-Segundo, L.
    Hernandez-Garcia, S.
    Gonzalez-Mendez, L.
    Algarin, E. M.
    Martin-Sanchez, M.
    Mateos, M. -V.
    Garayoa, M.
    Ocio, E. M.
    [J]. HAEMATOLOGICA, 2017, 102 : 501 - 501
  • [8] Activity of the pan-PIM kinase inhibitor INCB053914 in models of multiple myeloma
    Koblish, Holly
    Shin, Niu
    Hall, Leslie
    Wen, Xiaoming
    O'Connor, Sybil
    Dostalik, Valerie
    Wang, Qian
    Wang, Kathy
    Covington, Maryanne
    Marando, Cindy
    Bowman, Kevin
    Boer, Jason
    Burke, Krista
    Zhang, Ke
    Feng, Hao
    Xue, Chu-Biao
    Li, Yun-Long
    Yao, Wenqing
    Huber, Reid
    Vaddi, Kris
    Scherle, Peggy
    [J]. CANCER RESEARCH, 2015, 75
  • [9] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Sunami, Kazutaka
    Minami, Hironobu
    Hatake, Kiyohiko
    Sekiguchi, Risa
    Natsume, Kazuto
    Ishikawa, Norifumi
    Rinne, Mikael
    Taniwaki, Masafumi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 797 - 806
  • [10] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Kazutaka Sunami
    Hironobu Minami
    Kiyohiko Hatake
    Risa Sekiguchi
    Kazuto Natsume
    Norifumi Ishikawa
    Mikael Rinne
    Masafumi Taniwaki
    [J]. International Journal of Hematology, 2021, 113 : 797 - 806
12345